Five months after countries had adopted the use of the new malaria vaccine, branded as R21/Matrix-M, the World Health Organisation (WHO) has finally given its approval for mass deployment of the medicine for the prevention of malaria in children.
WHO which confirmed the approval, Monday, in a press statement, said it followed the recommendation follows advice from its Strategic Advisory Group of Experts on Immunisation and the Malaria Policy Advisory Group and was endorsed by the Director-General, Dr Tedros Ghebreyesus, on the back of the global body’s regular biannual meeting held on September 25 -29.
“As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two. Demand for the RTS,S vaccine far exceeds supply, so this second vaccine is a vital additional tool to protect more children faster, and to bring us closer to our vision of a malaria-free future,” Dr Ghebreyesus said.
The R21/Matrix-M malaria vaccine developed by the University of Oxford, manufactured and scaled up by the Serum Institute of India, is only the second vaccine the world has seen for a disease that has caused untold suffering for millennia.
WHO also issued recommendations on the advice of SAGE for new vaccines for dengue and meningitis, along with immunisation schedules and product recommendations for COVID-19.
However, the addition of R21 to the list of WHO-recommended malaria vaccines is expected to result in sufficient vaccine supply to benefit all children living in areas where malaria is a public health risk.
WHO Regional Director for Africa, Dr Matshidiso Moeti, emphasised the importance of this recommendation for the continent, saying, the second vaccine holds real potential to close the huge demand-and-supply gap.
Delivered to scale and rolled out widely, the two vaccines can help bolster malaria prevention and control efforts and save hundreds of thousands of young lives in Africa from this deadly disease.
At least 28 countries in Africa plan to introduce a WHO-recommended malaria vaccine as part of their national immunisation programmes.
Gavi, the Vaccine Alliance has approved providing technical and financial support to roll out malaria vaccines to 18 countries.
WHO also noted that the RTS,S vaccine will be rolled out in some African countries in early 2024, and the R21 malaria vaccine is expected to become available to countries in mid-2024.
According to Moeti, Nigeria has seen major progress but accounts for around 27 per cent of the global burden of malaria cases.
